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ABSTRACT
Group A streptococci (GAS) (n = 1313) isolated
from patients with clinical symptoms of pharyn-
gitis or tonsillitis attending a tertiary care hospital
in southern India during 1986–2002 were tested
for susceptibility to penicillin and erythromycin.
The overall erythromycin resistance rate was
2.7% (n = 36). During 1986–1993, erythromycin
resistance was observed in only one (2%) isolate
in 1987, but reappeared in 1994 (2.7%), increased
to 5.8% in 1999, and reached a maximum fre-
quency of 13.8% in 2002. All isolates were
susceptible to penicillin. The data indicate the
need for continued surveillance of susceptibility
patterns among GAS isolates in order to monitor
the development of antibiotic resistance.
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Infections caused by group A streptococci (GAS)
continue to cause signiﬁcantmorbidity andmortal-
ity in many parts of the world [1]. In industrial-
ised countries, they cause invasive diseases, such
as toxic shock syndrome and necrotising fasciitis,
while post-infection sequelae in developing coun-
tries include acute rheumatic fever, rheumatic
heart disease and post-streptococcal glomerulo-
nephritis [1,2]. Penicillin remains the drug of
choice for the treatment of GAS infections and
their sequelae [3], with macrolides recommended
for patients allergic to b-lactams. However, since
the ﬁrst description of erythromycin-resistant
GAS in 1955 [4], many countries have reported
varying frequencies of erythromycin resistance,
with a signiﬁcant global increase in the incidence
of resistance in recent years [5–7]. This increase in
resistance is mediated either through target modi-
ﬁcation caused by methylase activity encoded by
two classes of methylase genes, ermAM and
ermTR, or by an active drug-efﬂux pump encoded
by the mefA gene [8,9]. The increased use of
macrolides for the treatment of upper respiratory
tract infections has contributed greatly towards
the development of increased resistance. Con-
tinuous surveillance of the susceptibility patterns
of GAS should therefore be performed in order to
recommend appropriate guidelines for antibiotic
prescription.
There are few reports on erythromycin resist-
ance in GAS isolates from developing countries.
This study presents data collected from 1986
to 2002 regarding penicillin and erythromycin
resistance in GAS isolates from patients with
clinical symptoms of pharyngitis or tonsillitis in
a tertiary care hospital in southern India. The
panel of antibiotics tested varied over time, so
only data for erythromycin and penicillin are
presented here. The tertiary care centre is a
2100-bed hospital, situated in southern India,
with various medical and surgical specialties,
which include renal, bone marrow and liver
transplant units. The average daily number of
outpatients is c. 4000, and includes patients from
different parts of India, as well as some neigh-
bouring countries. The microbiology laboratory
is a centralised facility that processes both out-
patient and inpatient specimens (c. 108 500 speci-
mens annually).
Throat swabs from patients attending the out-
patient units of the Departments of Child Health
and Otorhinolaryngology with clinical symptoms
of pharyngitis or tonsillitis were processed on
sheep blood agar plates for the isolation of
b-haemolytic streptococci according to standard
procedures [10]. GAS were identiﬁed by the
micro-nitrous acid extraction procedure and
coagglutination technique, with antisera prepared
and standardised in our laboratory [11]. All GAS
isolates from throat cultures during this period
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were tested for antibiotic susceptibilities. The
precise antibiotic panel for susceptibility testing
was determined after consultation with local
physicians, with consequent modiﬁcations from
time to time, depending upon the site of infection,
availability of newer and cost-effective antibiotics,
and antibiotic usage by physicians. From 1986 to
2000, all GAS throat isolates were tested against
penicillin, ampicillin, erythromycin and cephalex-
in. However, because of the wide use of penicillin
and erythromycin for GAS tonsillitis, the panel
was eventually restricted to these two antibiotics.
Antibiotic susceptibility testing was performed
by disk diffusion [12] on Mueller–Hinton agar
plates (Hi Media, Mumbai, India) with penicillin
(10 U) and erythromycin (15 lg) disks (Sigma
Aldrich Chemicals Pvt. Ltd, Bangalore, India).
Regular quality control tests were performed with
Staphylococcus aureus strain ATCC 25923. Results
were recorded after incubation of the plates at
37C for 18 h.
Of 1313 isolates of GAS screened for resistance
to penicillin and erythromycin during the period
1986–2002, 36 (2.7%) were resistant to erythro-
mycin (Fig. 1). From 1986 to 1993, of the 424
isolates tested, a single isolate from 1987 (2% of
the isolates in that year) was resistant to erythro-
mycin, while 35 (3.9%) of the 889 isolates tested
during 1994–2002 were resistant. Resistance
reached a maximum of 13.8% in 2002. All 1313
isolates tested were susceptible to penicillin.
Overall, the data documented an increasing trend
in the incidence of erythromycin resistance
among GAS isolates from patients in southern
India during the 17 years preceding 2002. A
previous study [13], reporting the resistance
patterns of GAS isolates during 1970–1983,
observed that erythromycin resistance varied
from 1 to 2% in different years, with no resistance
seen in six intervening years. This increasing
trend of erythromycin resistance among GAS
causing throat infections in southern India is a
worrying observation, as erythromycin is an
important drug for individuals allergic to peni-
cillin. The fact that antibiotics are freely available
‘across the counter’ in pharmacies in India makes
it very difﬁcult to determine the actual use of
erythromycin in this population.
Although the ﬁrst report of erythromycin
resistance was in 1955 [5], resistance rates
remained low for many years [7]. However,
beginning in the early 1970s, widespread resist-
ance to erythromycin was reported in Japan,
where the rate increased from 2% in 1971 to
52% in 1974 [14]. In Scotland, Phillips et al. [15]
reported a dramatic increase in 1988 to 23% over
an 18-month period. Similar increases have been
reported elsewhere [6,16–19], including Spain,
where the resistance rate increased from 1.2% in
1990 to 34.8% in 2001 [19]. Interestingly, the
problem has remained at a lower level in north
America. However, in speciﬁc populations in the
USA, the resistance rate has been reported to be as
high as 48% [6]. In a study conducted in south-
western Pennsylvania [6], the monthly prevalence
of macrolide resistance varied from 0% to 41%,
while the overall resistance rate for an 8-month
period was 9.6%. This study concluded that the
problem of erythromycin resistance in the USA
may be more common than realised previously,
and that longitudinal surveillance of GAS iso-
lates from multiple centres is needed to deﬁne
the prevalence of erythromycin-resistant GAS
isolates.
Our own hospital has been monitoring eryth-
romycin resistance rates since 1970, and, to the
best of our knowledge, there are no similar long-
term data in the literature based on longitudinal
surveillance. Although a 12-fold increase in eryth-
romycin resistance was observed over 17 years,
the overall rate is still much lower than those
reported from many Western countries. This may
be a consequence of the relatively infrequent use
of erythromycin by local physicians, who prefer
to use penicillins to treat pharyngitis and other
infections caused by GAS. Further molecular
studies have been initiated to deﬁne the emm
types responsible for the increasing erythromycin
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Fig. 1. Erythromycin resistance among group A strepto-
cocci in patients from southern India.
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resistance. However, the present study highlights
the importance of continuous monitoring of sus-
ceptibility patterns in order to observe the devel-
opment of resistance over a period of time. Such
laboratory-based data will be of immense value in
countries, such as India, where there are no
controls on the prescription and use of antibiotics
in the community.
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ABSTRACT
Between January 2002 and December 2003, macro-
lide-resistant isolates of Staphylococcus aureus
(n = 45) and coagulase-negative staphylococci
(CoNS; n = 75) from a Greek hospital were
examined phenotypically for inducible clindamy-
cin resistance. The constitutive macrolide resist-
ance phenotype predominated (60%) in S. aureus,
followed by the inducible (35%) and the clinda-
mycin-susceptible (5%) phenotypes. In CoNS, the
inducible phenotype was more common than the
constitutive phenotype (50% vs. 41%). There was
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